ALK Abello inks neffy co-promotion deal in USA

3 May 2025

Danish allergy immunotherapy specialist ALK Abello (OMX: ALK B) has announced a four-year agreement with USA-based ARS Pharmaceuticals (Nasdaq: SPRY) to co-promote the neffy adrenaline (epinephrine) nasal spray to up to 9,000 named pediatricians in the USA. These paediatricians currently account for close to 10% of all adrenaline auto-injector prescriptions in the USA.

The agreement is expected to give ALK improved access to US pediatricians, providing also attractive synergies to ALK’s existing product portfolio. neffy is the only approved needle-free treatment for life-threatening type I allergic reactions, including anaphylaxis.

Both companies’ share edged up on the news, ALK gaining 1.7% to 155.80 kroner and ARS up 2.1% to $14.46.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK